A retrospective analysis
4200 EMR of patients at high risk for stroke with 1-year follow-up will be enrolled in the current study and analyzed by clinical decision support systems (CDSS MedicBK) utilizing a core laboratory.
Study Type
OBSERVATIONAL
Enrollment
4,200
Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
Evgeny Pokushalov
Novosibirsk, Russia
The percentage of guideline-based and personalized EBM recommendations
The percentage of guideline-based and personalized EBM recommendations acted on by clinicians for anticoagulant therapy in patients with AF. All discrepancies between routine and CDSS-recommended treatment resulting in frame of guideline-based therapy and personalized EBM therapy will be adjudicated by core laboratory.
Time frame: 1-year
Quantify the performance of the CDSS (MedicBK) algorithm
Quantify the performance of the CDSS (MedicBK) algorithm for presents treatment suggestions in frame of guideline-based therapy and personalized EBM therapy: the sensitivity, specificity, NPV, and PPV
Time frame: 1-year
1-year FU outcomes
Outcomes for all-cause mortality, thromboembolism (TE), bleeding, and the composite endpoint of any thromboembolism, cardiovascular death, or bleeding in relation to whether they were guideline-based treatment or personalized EBM treatment. Thromboembolism refers to stroke, transient ischemic attack, acute coronary syndrome, coronary intervention, cardiac arrest, peripheral embolism, and pulmonary embolism
Time frame: 1-year
Predictors
Predictors of guideline-based and personalized EBM adherence
Time frame: 1-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.